EMA Authorised: Bydureon (exenatide) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Bydureon (exenatide extended-release) for type 2 diabetes mellitus, with AstraZeneca AB as the marketing authorisation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Bydureon (exenatide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 20/11/2024